How GLP-1 pricing actually works

A GLP-1’s "price" is really several different numbers, and the gap between them is why the same drug can show a ~$1,300 sticker and a ~$349 cash price in the same week — and why your insurance coinsurance is often calculated on the big number. Here is the supply chain in plain language, drawn from government and nonpartisan sources. Educational, not financial advice.

Verified Jul 2026 · re-checked quarterlyBy the GLP1Zoom editorial teamWe compare, we don’t sell

A brand GLP-1 carries a high list price (WAC, roughly $970–$1,349 a month depending on the drug) that almost nobody actually pays. Manufacturers set list prices high and then pay large rebates to pharmacy benefit managers (PBMs) for good formulary placement, so the "net" price after rebates is much lower — but that net price is hidden, and your coinsurance is frequently charged on the high list price, not the rebated net. Meanwhile the manufacturers sell several GLP-1s directly for cash at ~$349–$499 a month. Understanding these layers explains why cash can beat insurance on these drugs. Prices are as of 2026 and move frequently.

Key takeaways

WAC (list price) is what the manufacturer sets, before discounts — roughly $970–$1,349/mo for brand GLP-1s (2026). Almost no one pays it.
Manufacturers set list high, then rebate down to PBMs for formulary placement; the rebated "net" price is much lower but hidden from you.
Your coinsurance is often calculated on the LIST price, not the rebated net — so a high list price costs YOU money even when the plan pays less.
The FTC (Jan 2025 report) found the big PBMs marked up some specialty generics enormously — up to 7,736% on certain pulmonary-hypertension generics in 2022 — and captured $7.3B in dispensing revenue above cost (2017–2022). That’s the middle of the chain at work.
Because of all this, manufacturer cash-pay (~$349–$499/mo) can beat running it through insurance on a high-coinsurance specialty tier.

The pricing terms, decoded

Term	What it means
WAC	Wholesale Acquisition Cost — the manufacturer’s list price to wholesalers, before rebates/discounts. The "sticker."
AWP	Average Wholesale Price — a published benchmark (historically ≈ WAC + 20% for brands). Not the real paid price.
NADAC	National Average Drug Acquisition Cost — CMS’s weekly survey of what pharmacies actually pay to buy the drug (before off-invoice rebates).
Net price	What’s left after manufacturer rebates and discounts — the real economics, but hidden until year-end reconciliation.

Why the sticker price is a fiction

The list price (WAC) is a number the manufacturer sets, and for brand GLP-1s it runs roughly $970 to $1,349 a month depending on the drug. Almost no one pays it. Insurers negotiate discounts, PBMs collect rebates, and the manufacturers themselves now undercut the list with direct cash-pay programs around $349–$499 a month. The sticker exists mostly as a starting point for negotiation — and, unfortunately, as the number your coinsurance may be based on.

The rebate wall: why list prices stay high

Here’s the counterintuitive part. Pharmacy benefit managers (PBMs) — the middlemen who run the drug benefit for your insurer — negotiate rebates off the list price in exchange for putting a drug in a favorable formulary spot. A higher list price can mean a bigger rebate, so there’s an incentive for list prices to stay high even as the real (net) price the plan pays comes down. The KFF and the Commonwealth Fund both describe this dynamic.

The problem for patients: if your plan charges coinsurance (a percentage), it’s often calculated on the list price, not the rebated net price — because the net isn’t even known until year-end. So a $1,300 list price with 25% coinsurance can cost you more than the drug’s real net cost to the plan.

What the FTC found about the middle of the chain

In January 2025 the Federal Trade Commission released its second interim staff report on PBMs ("Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated PBMs"). It found the three largest PBMs marked up numerous specialty generic drugs enormously — up to 7,736% over their estimated acquisition cost on certain pulmonary-hypertension generics in 2022 — and generated an estimated $7.3 billion in revenue above acquisition cost between 2017 and 2022. (That 7,736% figure is for specific specialty generics, not GLP-1s, but it illustrates how much value the middle of the chain can capture.)

Why cash can beat insurance here

Put it together and you get the GLP-1 paradox: a drug with a four-figure list price that a manufacturer will sell you for cash at ~$349–$499. If your plan puts the drug on a specialty tier with high coinsurance calculated on the list price, paying cash directly can genuinely be cheaper than "using your insurance." That’s why our cost tools compare the paths side by side rather than assuming insurance always wins.

See what you’d actually pay

Common questions about How GLP-1 pricing actually works

Why is my GLP-1 $1,300 on paper but $499 cash?

The $1,300 is the list price (WAC) — a number the manufacturer sets that almost no one actually pays. The manufacturer then rebates that price down for insurers, and separately sells the drug directly for cash at a much lower number (~$349–$499/mo for several GLP-1s in 2026). The sticker and the cash price are two different points in the same pricing system.

Why is my coinsurance based on the high list price?

Because the rebated "net" price your plan actually pays isn’t known until year-end reconciliation, coinsurance is frequently calculated on the list price instead. That means a high list price costs you real money even when your plan is paying much less after rebates — one of the most-criticized features of how the system works (KFF, Commonwealth Fund).

What is a PBM and why does it matter?

A pharmacy benefit manager is the middleman that runs the drug benefit for your insurer — building the formulary, negotiating rebates, and often owning the specialty pharmacy that dispenses your drug. The FTC has reported that the largest PBMs capture large markups in this role. It matters to you because their incentives help keep list prices high and can make cash-pay cheaper than insurance on specialty drugs.

Does this mean I should always pay cash?

Not always — if your plan covers the drug at a low flat copay, insurance may still win. The point is that on a high-coinsurance specialty tier, cash-pay (~$349–$499/mo) can beat insurance, so it’s worth comparing both. This is general education, not financial advice; run your actual numbers.

Sources

Last reviewed 2026-07-24.

How GLP-1 pricing actually works

The pricing terms, decoded

Term	What it means
WAC	Wholesale Acquisition Cost — the manufacturer’s list price to wholesalers, before rebates/discounts. The "sticker."
AWP	Average Wholesale Price — a published benchmark (historically ≈ WAC + 20% for brands). Not the real paid price.
NADAC	National Average Drug Acquisition Cost — CMS’s weekly survey of what pharmacies actually pay to buy the drug (before off-invoice rebates).
Net price	What’s left after manufacturer rebates and discounts — the real economics, but hidden until year-end reconciliation.

Why the sticker price is a fiction

The rebate wall: why list prices stay high

What the FTC found about the middle of the chain

Why cash can beat insurance here